Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ziv-aflibercept · 4 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| ziv-aflibercept | BIOLOGICAL | - |
DISEASE CHARACTERISTICS: * Histologically confirmed non-Hodgkin's lymphoma OR primary or metastatic solid tumor located in at least one of the following sites: * Liver * Soft tissue * Pelvis * Other site that is suitable for delayed contrast-enhancing MRI * Relapsed or refractory disease ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Ziv-aflibercept is an investigational monoclonal antibody being studied for use in cancer and lymphoma. It is being evaluated in patients with relapsed or refractory solid tumors and non-Hodgkin's lymphoma, as well as in unspecified adult solid tumors. The drug is in Phase 1 clinical development.
Ziv-aflibercept is being developed by Regeneron Pharmaceuticals, Inc., which trades under the ticker REGN. The company is conducting clinical trials of the drug in the United States for oncology indications including cancer and lymphoma.
Ziv-aflibercept is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The drug has received a priority review designation from the FDA, but it remains in early-stage clinical trials.
Ziv-aflibercept has been studied in four completed Phase 1 trials, including NCT00036946, NCT00045266, NCT00082823, and NCT00083213. These trials evaluated the drug in patients with relapsed or refractory solid tumors or non-Hodgkin's lymphoma, with a total enrollment of 50 patients across the studies.
Ziv-aflibercept is a distinct drug asset from aflibercept, though both are developed by Regeneron. Ziv-aflibercept is being studied specifically for cancer and lymphoma indications, while aflibercept is used for other conditions. The two drugs have different molecular structures and are not interchangeable.